These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 28611361)

  • 1. Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
    Kromann-Hansen T; Louise Lange E; Peter Sørensen H; Hassanzadeh-Ghassabeh G; Huang M; Jensen JK; Muyldermans S; Declerck PJ; Komives EA; Andreasen PA
    Sci Rep; 2017 Jun; 7(1):3385. PubMed ID: 28611361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand binding modulates the structural dynamics and activity of urokinase-type plasminogen activator: A possible mechanism of plasminogen activation.
    Kromann-Hansen T; Lange EL; Lund IK; Høyer-Hansen G; Andreasen PA; Komives EA
    PLoS One; 2018; 13(2):e0192661. PubMed ID: 29420634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection and characterization of camelid nanobodies towards urokinase-type plasminogen activator.
    Kaczmarek JZ; Skottrup PD
    Mol Immunol; 2015 Jun; 65(2):384-90. PubMed ID: 25749705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interconversion of active and inactive conformations of urokinase-type plasminogen activator.
    Liu Z; Kromann-Hansen T; Lund IK; Hosseini M; Jensen KJ; Høyer-Hansen G; Andreasen PA; Sørensen HP
    Biochemistry; 2012 Oct; 51(39):7804-11. PubMed ID: 22950516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
    Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
    J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
    Behrens MA; Botkjaer KA; Goswami S; Oliveira CL; Jensen JK; Schar CR; Declerck PJ; Peterson CB; Andreasen PA; Pedersen JS
    J Mol Biol; 2011 Aug; 411(2):417-29. PubMed ID: 21669207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Camelid-derived Antibody Fragment Targeting the Active Site of a Serine Protease Balances between Inhibitor and Substrate Behavior.
    Kromann-Hansen T; Oldenburg E; Yung KW; Ghassabeh GH; Muyldermans S; Declerck PJ; Huang M; Andreasen PA; Ngo JC
    J Biol Chem; 2016 Jul; 291(29):15156-68. PubMed ID: 27226628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The crystal structures of 3-TAPAP in complexes with the urokinase-type plasminogen activator and picrate.
    Zesławska E; Jacob U; Stürzebecher J; Oleksyn BJ
    Bioorg Med Chem Lett; 2006 Jan; 16(1):228-34. PubMed ID: 16202591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Light Chain Allosterically Enhances the Protease Activity of Murine Urokinase-Type Plasminogen Activator.
    Torres-Paris C; Song HJ; Engelberger F; Ramírez-Sarmiento CA; Komives EA
    Biochemistry; 2024 Jun; 63(11):1434-1444. PubMed ID: 38780522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator.
    Spraggon G; Phillips C; Nowak UK; Ponting CP; Saunders D; Dobson CM; Stuart DI; Jones EY
    Structure; 1995 Jul; 3(7):681-91. PubMed ID: 8591045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
    Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
    J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
    Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
    Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural investigations of recombinant urokinase growth factor-like domain.
    Beloglazova IB; Beabealashvilli RSh; Gursky YG; Bocharov EV; Mineev KS; Parfenova EV; Tkachuk VA
    Biochemistry (Mosc); 2013 May; 78(5):517-30. PubMed ID: 23848154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator.
    Crippa MP
    Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
    Jankun J; Skrzypczak-Jankun E
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation.
    Zhao B; Gandhi S; Yuan C; Luo Z; Li R; Gårdsvoll H; de Lorenzi V; Sidenius N; Huang M; Ploug M
    J Mol Biol; 2015 Mar; 427(6 Pt B):1389-1403. PubMed ID: 25659907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cleavage of peptidic inhibitors by target protease is caused by peptide conformational transition.
    Jiang L; Oldenburg E; Kromann-Hansen T; Xu P; Jensen JK; Andreasen PA; Huang M
    Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2017-2023. PubMed ID: 29959058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-directed discovery of potent non-peptidic inhibitors of human urokinase that access a novel binding subsite.
    Nienaber VL; Davidson D; Edalji R; Giranda VL; Klinghofer V; Henkin J; Magdalinos P; Mantei R; Merrick S; Severin JM; Smith RA; Stewart K; Walter K; Wang J; Wendt M; Weitzberg M; Zhao X; Rockway T
    Structure; 2000 May; 8(5):553-63. PubMed ID: 10801494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric inactivation of a trypsin-like serine protease by an antibody binding to the 37- and 70-loops.
    Kromann-Hansen T; Lund IK; Liu Z; Andreasen PA; Høyer-Hansen G; Sørensen HP
    Biochemistry; 2013 Oct; 52(40):7114-26. PubMed ID: 24079451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A structural mechanism of flavonoids in inhibiting serine proteases.
    Xue G; Gong L; Yuan C; Xu M; Wang X; Jiang L; Huang M
    Food Funct; 2017 Jul; 8(7):2437-2443. PubMed ID: 28644504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.